Topics

MS and ICI (Immune Checkpoint Inhibitor) Therapy

Cancer Immunotherapy Neurodegeneration Chronic Inflammation Cellular Degeneration

Immune checkpoint inhibitors create a difficult risk-benefit problem when cancer occurs in a person with multiple sclerosis. Antibodies blocking PD-1, PD-L1, or CTLA-4 can restore antitumor T-cell activity, but the same pathways help restrain autoreactive lymphocytes. Patients with pre-existing autoimmune neurologic disease were commonly excluded from pivotal oncology trials, so early decisions relied on case reports and concern that checkpoint blockade would provoke demyelinating relapse. Recent retrospective cohorts provide more direct evidence: many treated patients remained neurologically stable, yet new inflammatory activity and clinical exacerbations were documented in a minority. Cohort size, treatment selection, and incomplete neurologic follow-up limit precise risk estimation. These studies support individualized treatment rather than a universal prohibition, while emphasizing that the evidence base remains small and selected[1][2].

The biological tension arises from overlapping requirements for tumor immunity and self-tolerance. PD-1 signaling limits activation and tissue damage after antigen recognition, whereas CTLA-4 competes with CD28 for CD80 and CD86 during T-cell priming. Blocking these brakes can expand tumor-reactive clones but may also reactivate myelin-directed T cells, enhance antigen presentation, and amplify inflammatory cytokines within the central nervous system. Blood-brain barrier disruption and resident microglial activation may magnify a peripheral immune perturbation once inflammation enters neural tissue. Checkpoint inhibitors have additionally been associated with de novo central nervous system demyelination in people without known multiple sclerosis, producing optic neuritis, transverse myelitis, encephalopathic syndromes, or lesions resembling multiple sclerosis. In patients with established disease, withdrawal of disease-modifying therapy around cancer treatment may further confound attribution of relapse to the checkpoint inhibitor itself[2][3].

In practice, the potential oncologic benefit, cancer alternatives, prior multiple sclerosis activity, disability, lesion burden, and current immunotherapy should be considered together. Baseline neurologic examination and magnetic resonance imaging create a reference for subsequent symptoms. Coordination between oncology and neuroimmunology is particularly important when a patient has recent relapses, active enhancing lesions, or must interrupt a disease-modifying treatment. The plan should specify who will evaluate new symptoms and how rapidly imaging and treatment can be arranged. New weakness, sensory loss, visual change, gait deterioration, or cognitive symptoms require prompt evaluation because infection, metastasis, paraneoplastic disease, treatment toxicity, and multiple sclerosis activity can look similar. When inflammatory demyelination is suspected, checkpoint interruption and immunosuppression may be necessary, but management must preserve antitumor control whenever possible[1][3].

Major gaps include the absence of prospective comparative studies, inconsistent definitions of relapse, and limited information about individual disease-modifying therapies used concurrently with checkpoint blockade. Registries should record neurologic history, imaging, treatment interruption, checkpoint class, cancer response, corticosteroid exposure, and long-term disability using standardized measures. Studies must also separate radiographic activity from clinically meaningful relapse and analyze older and progressive multiple sclerosis independently. Biomarkers that distinguish transient immune activation from pathogenic autoreactivity could improve surveillance, while pharmacologic strategies that preserve peripheral tumor killing without releasing central nervous system tolerance remain an important goal. Until stronger data emerge, checkpoint therapy should be framed as a monitored, shared decision: real neurologic risk exists, but available cohorts do not justify denying effective cancer therapy solely because of the diagnosis[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L027 Antiviral Compound Library
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs. MCE designs a unique collection of 1,237 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Disease Focused Libraries

104
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L007 Immunology/Inflammation Compound Library
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 8,643 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Signaling Pathway Targeting Libraries

89
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L109 Protein-protein Interaction Inhibitor Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Signaling Pathway Targeting Libraries

86
HY-L054 Endoplasmic Reticulum Stress Compound Library
Endoplasmic reticulum (ER) contributes to the production and folding of approximately one third of cellular proteins, and is thus inextricably linked to the maintenance of cellular homeostasis and the fine balance between health and disease. However, some adverse factors negatively impact ER functions and protein synthesis, resulting in the activation of Endoplasmic reticulum stress (ER stress, ERS) and unfolded protein response (UPR) signaling pathways. The UPR is triggered when ER protein folding capacity is overwhelmed by cellular demand and the UPR initially aims to restore ER homeostasis and normal cellular functions. However, if this fails, then the UPR triggers cell death. Chronic ER stress and defects in UPR signaling are emerging as key contributors to a growing list of human diseases, including diabetes, neurodegeneration and cancer. MCE Endoplasmic Reticulum Stress Compound Library contains 379 ER stress-related compounds that mainly target PERK, IRE1, ATF6, etc. MCE ER stress library is a useful tool for researching ER stress and related diseases.

Signaling Pathway Targeting Libraries

85
HY-L070 Neuroprotective Compound Library
Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases. MCE offers a unique collection of 1,851 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Compound Characteristic Classified Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L047 Endocrinology Compound Library
The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function. The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease. MCE offers a unique collection of 908 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Disease Focused Libraries

83
HY-L062 Neurotransmitter Receptor Compound Library
Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding. In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy. MCE designs a unique collection of 2,593 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L105 Peptide Library
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,647 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Structure Classified Libraries

83
HY-L118 Sodium Channel Blocker Library
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 199 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Signaling Pathway Targeting Libraries

83
HY-L140 Withdrawn Drug Compound Library
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Drug Repurposing Series

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L225 Cardiotoxic Compound Library
Drug development is both expensive and time-consuming, with approximately one-third of drug discontinuations caused by severe adverse drug reactions (ADRs). Among these, drug-induced cardiotoxicity (DICT) is one of the primary reasons for late-stage clinical drug failures and market withdrawals. To date, cardiotoxicity has been observed in multiple drug classes, such as anticancer drugs, antipsychotics, antidepressants, antibiotics, and neurodegenerative disease medications. To reduce cardiac ADRs, it is crucial to determine the clinical relevance of DICT to treatment, elucidate the underlying molecular mechanisms, identify reliable biomarkers, and develop new diagnostic and therapeutic approaches. MCE offers 260 cardiotoxicity compounds, including some FDA-approved drugs as well as inhibitors/blockers of the hERG potassium channel.
83
HY-L255 Dipeptide Compound Library
Dipeptide compounds have attracted extensive attention in drug discovery and life science research due to their simple structures, ease of modification, and favorable biocompatibility. As small peptides composed of two amino acids, dipeptides exhibit diverse biological activities, including anti-inflammatory, antioxidant, antimicrobial, anticancer, and immunomodulatory effects, showing significant application potential in metabolic disorders, neurological diseases, and cancer research. Compared with traditional small molecules, dipeptide compounds possess favorable target-binding properties and high structural plasticity, making them valuable tools for drug screening and mechanism studies. The MCE Dipeptide Compound Library contains 72 dipeptide compounds and can be applied to peptide drug discovery and development.

Structure Classified Libraries

83
HY-L919 MCE CNS BBB Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Focused and target libraries

83
HY-L920 CNS MPO Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.

Focused and target libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-17363 Dimethyl fumarate
Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
Keap1-Nrf2   Reactive Oxygen Species (ROS)   HIV   Autophagy   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Viral Infection   Obesity   Lung Fibrosis  
65
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902A Pembrolizumab (anti-PD-1)
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

Species: Human

PD-1/PD-L1  
Triple-Negative Breast Cancer  
37
HY-12495A ISRIB
ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research.
Biochemical Assay Reagents   Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
37
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-D0836 EDTA dipotassium dihydrate
EDTA dipotassium dihydrate is a metal ion chelator that forms stable and water-soluble chelates with a variety of metal ions. EDTA dipotassium is commonly used as a blood anticoagulant, which can effectively prevent blood coagulation and maintain the morphology and function of cells in blood samples. In the industrial field, EDTA dipotassium can be used to remove the adverse effects of metal ions and prevent oxidation and deterioration caused by metal ions.
DNA/RNA Synthesis  
33
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-Y0304 Dibutyl phthalate
Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Environmental Pollutants  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer  
12
HY-N0127 Yohimbine Hydrochloride
Yohimbine hydrochloride is an alpha-2 renal adenomatase receptor inhibitor, blocking pre- and post-contact alpha-2 renal adenomatase receptors, causing the release of renal adenoma and multiple sclerosis.
Adrenergic Receptor  
Depression   Glucose Metabolism   SARS-CoV-2 Infection   Alzheimer's Disease   Hypertension  
11
HY-P1240B MOG (35-55) acetate
MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate is a minor component of CNS myelin. MOG (35-55) (acetate) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (acetate) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (acetate) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
9
HY-P1240A MOG (35-55) TFA
MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
9
HY-P1240 MOG (35-55) mouse, rat
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Endogenous Metabolite  
Epilepsy   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
9
HY-101878 Texas Red
Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
8
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-P9901 Ipilimumab
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Metastatic Melanoma  
5
HY-102022 α-Galactosylceramide
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).
Transmembrane Glycoprotein   Interleukin Related   CD1  
Inflammation or Immune System Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Hepatitis Virus Infection  
4
HY-P80609 CD86 Antibody
CD86 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CD86.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

4
HY-P81169A PD-1 Antibody(YA3401)
PD-1 Antibody(YA3401) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

4
HY-P99048A Sintilimab (Anti-PD-1)
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Lung Squamous Cell Carcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
3
HY-P1812A AUNP-12 TFA
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Cancer  
3
HY-101889 Cresyl Violet perchlorate
Cresyl Violet perchlorate is a red fluorescent stain, which can be used to stain neurons.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
3
HY-P1812 AUNP-12
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer  
3
HY-P990824 Anti-Mouse PD-1 Antibody (J43)
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer.

Species: Mouse

PD-1/PD-L1  
Breast Cancer   Prostate Cancer  
3
HY-B0883 3,6-Diaminoacridine hemisulfate
3,6-Diaminoacridine hemisulfate is a multifunctional acridine compound. 3,6-Diaminoacridine hemisulfate is an acridine dye and also a DNA inserter. 3,6-Diaminoacridine hemisulfate is a potent broad-spectrum antibacterial agent. Its mechanism is to insert into bacterial DNA, interfering with replication and transcription, leading to bacterial lysis. 3,6-Diaminoacridine hemisulfate is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine hemisulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus. Long-term exposure may induce skin cancer or other malignant tumors.
Bacterial   Fluorescent Dye   Potassium Channel   DNA/RNA Synthesis  
Cancer   Infection   Neurological, Eye or Ear Disease  
3
HY-32350 Ercalcitriol
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
VD/VDR   Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
3
HY-108829A Abatacept (powder)
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-101888 Cresyl Violet acetate
Cresyl Violet acetate is a dye, which can be used to stain neurons.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
3
HY-W004284 Heptadecanoic acid
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis.
Apoptosis   Akt   PI3K  
Pancreatic Cancer   Cardiovascular Disease   Glucose Metabolism   Multiple Sclerosis  
3
HY-P99132 Anti-Mouse CTLA-4 Antibody (9D9)
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8+ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma.

Species: Mouse

CTLA-4  
Inflammation or Immune System Disease   Colorectal Cancer   Melanoma  
3
HY-P99042 Polatuzumab
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity.

Species: Human

Transmembrane Glycoprotein   ADC Antibodies  
CNS Neoplasm   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
3
HY-164992 Trastuzumab vedotin
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
Antibody-Drug Conjugates (ADCs)   EGFR   Microtubule/Tubulin  
Gastric Cancer   Metastatic Breast Cancer   Urothelial Cancer  
3
HY-P99126 Anti-Mouse/Human CD44 Antibody (IM7)
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma.

Species: Human/Mouse

Transmembrane Glycoprotein   CD44  
Cancer   Inflammation or Immune System Disease   Arthritis  
3
HY-108829 Abatacept
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Lung Cancer   Melanoma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-P0271 Syntide 2
Syntide 2, a Ca2+- and calmodulin (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected.
CaMK   Autophagy  
Neurological, Eye or Ear Disease  
2
HY-P0271A Syntide 2 TFA
Syntide 2 (TFA), a Ca2+- and calmodulin (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected.
CaMK  
Neurological, Eye or Ear Disease  
2
HY-Y0808 Dimethyl succinate
Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease.
Environmental Pollutants   Apoptosis  
Metabolic or Endocrine Disease   Alzheimer's Disease  
2
HY-W040074 Glycylglycine hydrochloride hydrate
Glycylglycine hydrochloride hydrate is a non-selective Glycylglycine hydrochloride hydrate dipeptidase substrate and iNOS inhibitor. Glycylglycine hydrochloride hydrate can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine hydrochloride hydrate promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine hydrochloride hydrate can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis).
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
1
HY-P10908 H-20
H-20 is a PD-1 agonist. H-20 can be used in the research of chronic pain.
PD-1/PD-L1  
Lung Cancer  
1
HY-P99891 Rovelizumab
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.

Species: Human

Integrin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P99524 Vatelizumab
Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis.

Species: Human

Integrin  
Multiple Sclerosis  
1
HY-N0460 1-Caffeoylquinic acid
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the Inhibitor for PD-1/PD-L1.
NF-κB   PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Parkinson's Disease   Obesity  
1
HY-N10574A Queuine dihydrochloride
Queuine dihydrochloride is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine dihydrochloride promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine dihydrochloride is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine dihydrochloride can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells.

Source: eubacteria

Others  
Metabolic or Endocrine Disease  
1
HY-128700 Nicotinic acid mononucleotide
Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD+ biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD+ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD+ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.
Endogenous Metabolite   Sirtuin  
Cancer   Huntington's Disease   Multiple Sclerosis  
1
HY-113100 N-Acetylputrescine hydrochloride
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Lung Cancer   Parkinson's Disease  
1
HY-D0889 Glycylglycine
Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis).
Endogenous Metabolite  
Neurodegenerative Disease   Male Reproductive System Disease  
1
HY-W342604 N-Acetylputrescine
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Parkinson's Disease  
1
HY-N10574 Queuine
Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells.

Source: eubacteria

Bacterial  
Metabolic or Endocrine Disease  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-P990008 Atrosab
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TNF Receptor   Apoptosis  
Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis   Rheumatoid Arthritis  
1
HY-132253 Polatuzumab vedotin
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
Antibody-Drug Conjugates (ADCs)   Transmembrane Glycoprotein  
Leukemia/Lymphoma/Myeloma  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-Y1089 4-Dimethylaminopyridine
4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks.
Biochemical Assay Reagents   Transmembrane Glycoprotein  
Neurological, Eye or Ear Disease  
1
HY-103048 PD-1/PD-L1-IN 3
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-184075S Nomelcitinib
Nomelcitinib is a TYK2 inhibitor that modulates the IL23 signaling pathway. Nomelcitinib is used for research on multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.
JAK   Interleukin Related  
Digestive System Disease   Digestive System Inflammation   Systemic Lupus Erythematosus   Multiple Sclerosis   Crohn's Disease   Psoriasis   Rheumatoid Arthritis  
/
HY-B1139S Tolperisone-d10 hydrochloride
Tolperisone-d10 (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.
Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-P991351 RTX-002
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-DP99144F1 Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled
Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled, is an Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144) derivative carrying dye CY7 (HY-D0825). Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P1521 β-Amyloid (15-21)
β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-Y0304S2 Dibutyl phthalate-13C2
Dibutyl phthalate-13C2 is the 13C-labeled Dibutyl phthalate (HY-Y0304). Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Isotope-Labeled Compounds   Environmental Pollutants  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P1052 Myelin Basic Protein(87-99)
Myelin Basic Protein(87-99) is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).
Others  
Inflammation or Immune System Disease  
/
HY-P4072 (D)-PPA 1
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.
PD-1/PD-L1  
/
HY-13599S4 Cladribine-13C,15N2
Cladribine-13C,15N2 (2-Chloro-2′-deoxyadenosine-13C,15N2) is the 13C- and 15N-labeled Cladribine (HY-13599). Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active?adenosine deaminase?inhibitor. Cladribine functions as an inhibitor of?DNA synthesis?to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
Isotope-Labeled Compounds   Adenosine Deaminase   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P1053 β-Amyloid (10-20)
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-W753956 Iminostilbene-d10
Iminostilbene-d10 is the deuterium labeled Iminostilbene (HY-N7064). Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
Isotope-Labeled Compounds   COX   HIF/HIF Prolyl-Hydroxylase   Pyruvate Kinase   TNF Receptor   Interleukin Related   STAT   NO Synthase  
Inflammation or Immune System Disease  
/
HY-12355S Siponimod-d11
Siponimod-d11 (BAF-312-d11) is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
Isotope-Labeled Compounds   Potassium Channel   LPL Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-B0167E Salicylic acid Sterile Solution (1 mg/ml)
Salicylic acid Sterile Solution (1 mg/mL) is a sterile solution suitable for plant culture. Salicylic acid (HY-B0167) is a weak acid that, once inside the plant, can activate growth regulators such as nitric oxide, thereby influencing plant growth and development. Salicylic acid can also regulate plant cell metabolism and membrane permeability, improving the plant's resistance to adverse conditions.
Biochemical Assay Reagents  
/
HY-P991536 KHK6640
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease.

Species: Human

Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N0460R 1-Caffeoylquinic acid (Standard)
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the inhibitor for PD-1/PD-L1.
Reference Standards   NF-κB   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N20348 Anemarrhena extract
Anemarrhena extract (Rhizoma anemarrhenae extract) is an extract of Anemarrhena rhizome that can be used for research on neurological diseases.
Others  
Neurological, Eye or Ear Disease  
/
HY-P3541 Dirucotide
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein. Dirucotide can be used for the research in autoimmune disorder of the central nervous system, such as Multiple sclerosis (MS).
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-103684 RT-NH2
RT-NH2 is a RealThiol prototype without the carboxylic acid groups. RT-NH2 is fairly hydrophobic and cannot distribute in the nucleus, which is a hallmark of protein binding for fluorescent probe.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
/
HY-P10838 PL120131
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors.
PD-1/PD-L1   Apoptosis  
Breast Cancer  
/
HY-N9878 Pistaciamide
Pistaciamide is an N-phenyl-pyrrolidone derivative, and its related pyrrolidone derivatives are commonly used in the treatment of neurological disorders, making it relevant for research of neurological dysfunction. Pistaciamide can be naturally extracted from the 90% ethanol extract of fresh shoots and inflorescences of Pistacia chinensis Bunge. (a plant of the Anacardiaceae family).
Others  
Nervous System Injury  
/
HY-P991725 Velvakiment
Velvakiment is a humanized VHH nanobody that targets IL-17A. Velvakiment can be used for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis research.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P990229 Anti-Rat IgG2b Antibody (RG7/11.1)
Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2b monoclonal antibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control.

Species: Mouse

Others  
Infection   Neurological, Eye or Ear Disease  
/
HY-111613S Pinaverium bromide-d4
Pinaverium bromide-d4 is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients.
Isotope-Labeled Compounds   Calcium Channel  
/
HY-145771 PD-1/PD-L1-IN-20
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.
PD-1/PD-L1  
Cancer  
/
HY-P991596 ANB004
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P10522 MBP Ac1-9
MBP Ac1-9 refers to a peptide fragment of myelin basic protein (MBP). MBP Ac1-9 is an immunodominant epitope in the experimental autoimmune encephalomyelitis (EAE) model, which can induce T cell immune response and lead to pathological changes similar to multiple sclerosis. MBP Ac1-9 can be used to study T cell activation and autoimmune response.
Others  
/
HY-P11046 IIIM1
IIIM1 is an orally active anti-inflammatory peptide. IIIM1 ameliorates the symptoms of experimental autoimmune encephalomyelitis (EAE) by stimulating the proliferation of regulatory T cells and inducing them to produce RA1, and regulating the cytokine balance. IIIM1 can be used in the research of multiple sclerosis (MS).
Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P3724 MBP (146-170)
MBP (146-170) is a myelin basic protein (MBP). MBP (146-170) can be used for the research of multiple sclerosis (MS).
Others  
Inflammation or Immune System Disease  
/
HY-P4623 Penta-alanine
Penta-alanine (Penta-L-alanine) is a petide. Penta-alanine can be used for neurological disease research.
Others  
Neurological, Eye or Ear Disease  
/
HY-P1510 β-Amyloid (1-11)
β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N12537A (2R,3S)-PD-1/PD-L1-IN-38
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1.
Aryl Hydrocarbon Receptor   PD-1/PD-L1  
Cancer  
/
HY-P1996 Tiplimotide
Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS).
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-D2266 FluoBar1
FluoBar1 is an imaging fluorescence probe modified by a barbiturate ligand with fluorescent coumarin. FluoBar1 can monitor L-type voltage-gated calcium channels (LTCC) in living cells in real time for the study of neurological diseases .
Fluorescent Dye  
Neurological, Eye or Ear Disease  
/
HY-Y0304R Dibutyl phthalate (Standard)
Dibutyl phthalate (Standard) is the analytical standard of Dibutyl phthalate. This product is intended for research and analytical applications. Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Biochemical Assay Reagents   Reference Standards  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P10826 PD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model.
PD-1/PD-L1  
Cancer  
/
HY-175310S Voderdeucitinib
Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD).
JAK  
Inflammation or Immune System Disease  
/
HY-W854549 Heparin pentasaccharide
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
Factor Xa  
Blood or Cardio-cerebrovascular Disease  
/
HY-176344S PD1, Arg-13C6,15N4, Lys-13C6,15N2
PD1, Arg-13C36, 15N4, Lys-13C6, 15N2 is the 13C- and 15N-labeled PD1.
Isotope-Labeled Compounds  
Cancer  
/
HY-16900G Rolipram (GMP)
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
Phosphodiesterase (PDE)   Epigenetic Reader Domain   Amyloid-β  
Depression   Glioblastoma Multiforme   Alzheimer's Disease   Multiple Sclerosis  
/
HY-N21625 Pleioside B
Pleioside B is a flavonoid glycoside found in the leaves of Pleioblastus amarus and acts as a B lymphocyte stimulator. Pleioside B stimulates the proliferation of murine B lymphocytes in vitro. Pleioside B can be used in research on immune-related diseases.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-W710400 Quifenadine-d10
Quifenadine-d10 is the deuterium labeled Quifenadine (HY-122761). Quifenadine (Compound 3a), the hydroxyl-(diphenyl)methyl quinuclidine derivative, is a M3 receptor antagonist with an IC50 value > 1000 nM. Quifenadine can be used for the research of neurological disease.
Isotope-Labeled Compounds   mAChR  
Neurological, Eye or Ear Disease  
/
HY-P991590 1D09C3
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).

Species: Human

MHC   Apoptosis   JNK   Reactive Oxygen Species (ROS)  
Cancer  
/
HY-N12537 PD-1/PD-L1-IN-38
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8+ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity.
PD-1/PD-L1  
/
HY-B1637S Ditiocarb-d10 sodium
Ditiocarb-d10 sodium (Sodium diethyldithiocarbamate-d10) is the deuterium labeled Ditiocarb sodium (HY-B1637). Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases.
Isotope-Labeled Compounds   HIV   Biochemical Assay Reagents  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P10297 PLP (190-209)
PLP (190-209) is a myelin proteolipid protein (PLP) fragment. PLP (190-209) is used to induce experimental autoimmune encephalomyelitis (EAE) animal models for multiple sclerosis research.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-W321446 Dansyl ethylenediamine
Dansyl ethylenediamine is a fluorescent probe. Dansyl ethylenediamine can be used for synthesis of protein-imprinted polymers which is capable of specific transduction of protein binding events into fluorescent signal change.
Fluorescent Dye  
/
HY-Y0055S Phenothiazine-d8
Phenothiazine-d8 is the deuterium labeled Phenothiazine. Phenothiazine is an antibiotic which has insecticidal, fungicidal, antibacterial and anthelmintic activities. Phenothiazine also can be used for the research of neurological diseases.
Isotope-Labeled Compounds   Antibiotic   Fungal   Bacterial   Parasite  
Neurological, Eye or Ear Disease   Bacterial Infection  
/
HY-P10680 TFE-IDAtp1-LinA
TFE-IDAtp1-LinA is a highly potent amphiphilic carrier, containing a trifluoroethyl-iminodiacetic acid analog of Stp. TFE-IDAtp1-LinA, formed nanoparticles with Cas9 RNP/ssDNA, achieved enhanced green fluorescent protein knockouts with an ED50 of 0.38 nM Cas9/sgRNA ribonucleoproteins (RNP).
Liposome  
/
HY-165394 Melafolone
Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research.
COX   EGFR   PD-1/PD-L1   PI3K   Akt  
/
HY-N20119 Coffee fruit extract
Coffee fruit extract is an extract from the fruit of the coffee plant (Coffea) that can be used in research on neurological diseases.
Others  
Neurological, Eye or Ear Disease  
/
HY-N21759 Dendroside D
Dendroside D is a sesquiterpenoid compound. Dendroside D binds to the RNA site of RNA-dependent RNA polymerase and the active site of SARS-CoV-2 main protease through hydrogen bonds, electrostatic interactions, and hydrophobic interactions, thereby blocking viral replication. Dendroside D stimulates the proliferation of mouse T and B lymphocytes, promotes T and B lymphocyte proliferation, and exhibits immunomodulatory activity. Dendroside D can be used for viral infection and immune-related research.
Endogenous Metabolite   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Viral Infection  
/
HY-W718815 Novaluron-d3-1
Novaluron-d3-1 is the deuterium labeled Novaluron (HY-17519). Novaluron is a chemical with?insecticide?properties, an insect growth regulator, and has adverse effects on mouse sperm.
Isotope-Labeled Compounds   Insecticide   Environmental Pollutants  
Infection  
/
HY-107803 Geranium oil
Geranium oil serves as a partial agonist for estrogen receptor (ER), enhancing both the cytotoxicity induced by Tamoxifen (TMX) (HY-13757A) in GT1-7 cells and the adverse effects of TMX on the central nervous system. Geranium oil can be utilized in the research of neurological disorders such as dementia.
Estrogen Receptor/ERR  
Neurological, Eye or Ear Disease  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-101888R Cresyl Violet acetate (Standard)
Cresyl Violet acetate (Standard) is the analytical standard of Cresyl Violet acetate (HY-101888). This product is intended for research and analytical applications. Cresyl Violet acetate is a dye, which can be used to stain neurons.
Fluorescent Dye   Reference Standards  
/
HY-101878R Texas Red (Standard)
Texas Red (Standard) is the analytical standard of Texas Red (HY-101878). This product is intended for research and analytical applications. Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations.
Fluorescent Dye   Reference Standards  
/
HY-P990819 Anti-Rat CD28 Antibody (JJ316)
Anti-Rat CD28 Antibody (JJ316) is a mouse-derived agonistic IgG1 κ type antibody, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ316) can induce T cell proliferation. Anti-Rat CD28 Antibody (JJ316) can be used for the researches of inflammation, immunology and neurological disease, such as experimental autoimmune encephalomyelitis (EAE) and graft-versus-host disease (GvHD).

Species: Rat

CD28  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P990793 Anti-Mouse CD28 Antibody (D665)
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Species: Mouse

CD28  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-13599S2 Cladribine-15N
Cladribine-15N (2-Chloro-2′-deoxyadenosine-15N) is 15N labeled Cladribine. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
Isotope-Labeled Compounds   Adenosine Deaminase   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-13599S Cladribine-d4
Cladribine-d4 (2-Chloro-2′-deoxyadenosine-d4) is deuterium labeled Cladribine. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
Isotope-Labeled Compounds  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-13599S1 Cladribine-13C5,15N2
Cladribine-13C5,15N2 (2-Chloro-2′-deoxyadenosine-13C5,15N2) is 13C and 15N labeled Cladribine. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
Isotope-Labeled Compounds  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-32350S1 Ercalcitriol-d3
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
Isotope-Labeled Compounds   VD/VDR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-165645 Protectin D1-d5
Protectin D1-d5 (Neuopotecti D1-d5) is deuterium labeled Protectin D1.
Isotope-Labeled Compounds  
/
HY-W653975 Bisphenol B-d8
Bisphenol B-d8 is the deuterium labeled Bisphenol B (HY-W013935). Bisphenol B is a very close structural analog of Bisphenol A (HY-18260), an endocrine disrupting chemical (EDC). Bisphenol B shows endocrine disruptive properties or other adverse effects on animal models.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-121892 (Z)-KC02
(Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo.
TNF Receptor  
Neurological, Eye or Ear Disease  
/
HY-W025830 2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid
2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid has neurological properties and can be used to study the structure and function of proteins and enzymes, as well as protein-protein interactions. 2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid can also be used to study the structure and function of compounds.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-P1052A Myelin Basic Protein(87-99) TFA
Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).
PKC  
Inflammation or Immune System Disease  
/
HY-13010S Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
Isotope-Labeled Compounds   NF-κB   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P991079 Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P99855 Divozilimab
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.

Species: Human

CD20  
Inflammation or Immune System Disease  
/
HY-P2478 Human PD-L1 inhibitor V
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P10838A PL120131 acetate
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors.
PD-1/PD-L1   Apoptosis  
Cancer  
/
HY-P4928A Biotinyl-Amylin (mouse, rat) TFA
Biotinyl-Amylin (mouse, rat) TFA is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P990778 Xirestomig
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs).

Species: Human

TNF Receptor   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P99895 Rulonilimab
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-69166 1H-Indazol-5-ol
1H-Indazol-5-ol is a porcine DAAO inhibitor with an IC50 value of 2.03 μM. 1H-Indazol-5-ol can be used in the research of neurological disorders.
Amino Acid Oxidase  
Neurological, Eye or Ear Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-136213 Endoplasmic reticulum dye 1
Endoplasmic reticulum dye 1 is a rhenium (I)-based luminescent, membrane-permeable cell imaging reagent with low cytotoxicity, photobleaching resistance, and suitability for multicolor imaging. Endoplasmic reticulum dye 1 localizes to the nuclear membrane, endoplasmic reticulum, and nucleoplasmic reticulum in live cells. Endoplasmic reticulum dye 1 enables detection of exocytosis events, dynamic changes in nuclear membrane-derived phagosomes, and vesicle trafficking processes.
Fluorescent Dye  
/
HY-P990259 Anti-Mouse CD96 Antibody (3.3)
Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma.

Species: Mouse

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-103048A PD-1/PD-L1-IN 3 TFA
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-W004284R Heptadecanoic acid (Standard)
Heptadecanoic acid (Standard) is the analytical standard of Heptadecanoic acid. This product is intended for research and analytical applications. Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis[1].
Reference Standards   Apoptosis   PI3K   Akt  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P4928 Biotinyl-Amylin (mouse, rat)
Biotinyl-Amylin (mouse, rat) is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-17363R Dimethyl fumarate (Standard)
Dimethyl fumarate (Standard) is the analytical standard of Dimethyl fumarate. This product is intended for research and analytical applications. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
Reference Standards   Keap1-Nrf2   Reactive Oxygen Species (ROS)   HIV   Autophagy   Endogenous Metabolite  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P991114 Adezkibart
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases.

Species: Human

FLT3  
Inflammation or Immune System Disease  
/
HY-150058 Bocconoline
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD).
Others  
Neurological, Eye or Ear Disease  
/
HY-P990283 Anti-Mouse CD22 Antibody (Cy34.1)
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis.

Species: Mouse

CD22  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P4072A (D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.
PD-1/PD-L1  
/
HY-P991078 Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-N3431 Kaempferol-7-O-rhamnoside
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure.
AMPK   PD-1/PD-L1   FXR   Reactive Oxygen Species (ROS)  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
/
HY-Y0304S1 Dibutyl phthalate-d22
Dibutyl phthalate-d22 is the deuterium labeled Dibutyl phthalate. Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Isotope-Labeled Compounds  
Cancer  
/
HY-P99484 Botensilimab
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer  
/
HY-17363S1 Dimethyl fumarate-d2
Dimethyl fumarate-d2 is the deuterium labeled Dimethyl fumarate. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
Autophagy   HIV   Keap1-Nrf2   Endogenous Metabolite   Reactive Oxygen Species (ROS)  
Cancer  
/
HY-P990169 Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry.

Species: Human/Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P99959 Unasnemab
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments.

Species: Human

TGF-β Receptor  
Neurological, Eye or Ear Disease  
/
HY-P99943 Erfonrilimab
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

Species: Human

PD-1/PD-L1   CTLA-4  
Non-Small Cell Lung Cancer   Nasopharyngeal Cancer  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-120967 (2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer.
p38 MAPK   Akt   Interleukin Related  
Cancer  
/
HY-W004284S1 Heptadecanoic acid-d33
Heptadecanoic acid-d33 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
Endogenous Metabolite  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99213 Ozanezumab
Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonal antibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis[1].

Species: Human

Others  
Amyotrophic Lateral Sclerosis   Multiple Sclerosis  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P990690 Volrustomig
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.

Species: Human

PD-1/PD-L1   CTLA-4  
Gastric Cancer   Liver Cancer   Cervical Cancer   Non-Small Cell Lung Cancer  
/
HY-W018597 2-Chloro-N-methylethanamine hydrochloride
2-Chloro-N-methylethanamine hydrochloride is a nitro compound that can be used to synthesize PD-1 inhibitors.
Biochemical Assay Reagents  
/
HY-N0534 Vitexin-2"-O-rhamnoside
Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC50 of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases.
DNA/RNA Synthesis   Apoptosis   PI3K   Akt   Caspase   SOD   Interleukin Related  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-P99359 Elezanumab
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.

Species: Human

TGF-beta/Smad  
Metabolic or Endocrine Disease   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P990789 Anti-Mouse CTLA-4 Antibody (9H10)
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.

Species: Mouse

CTLA-4  
Breast Cancer   Prostate Cancer  
/
HY-113366 Prostaglandin J2
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD).
Prostaglandin Receptor   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P3507 Dalazatide
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
Potassium Channel  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P3507A Dalazatide TFA
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
Potassium Channel  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P9960 Ocrelizumab
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).

Species: Human

CD20  
Inflammation or Immune System Disease  
/
HY-P991628 SSGJ-707
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer.

Species: Human

PD-1/PD-L1   VEGFR  
Colorectal Cancer   Small Cell Lung Cancer   Non-Small Cell Lung Cancer  
/
HY-110252 Salvinorin B
Salvinorin B is a selective and brain-penetrant kappa opioid receptor (KOPr) agonist with an EC50 of 248 nM and Ki of 2.95 μM. Salvinorin B activates downstream signaling pathways by binding to KOPr, inhibits pain transmission and reduces inflammatory response. Salvinorin B can be used for the researches of inflammation, immunology and neurological disease, such as neuropathic pain, multiple sclerosis and anxiety.
Opioid Receptor  
Inflammation or Immune System Disease   Depression   Pain  
/
HY-D1005A6 Poloxamer 124 (L44)
Poloxamer 124 L44 is a block polymer of polyoxyethylene and polyoxypropylene and a hydrophobic surfactant. Poloxamer 124 L44 causes eye irritation and exhibits oral toxicity in albino rats with an LD50 of 5 g/kg. Poloxamer 124 L44 has reversible adverse effects on triglyceride and cholesterol transport in the lymphatic system of rats. Poloxamer 124 L44 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering[1][2][3].
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P990788 Anti-Mouse PD-1 Antibody (29F.1A12)
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P9965 Elotuzumab
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P99486 Briakinumab
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P990792 Anti-Mouse CD4 Antibody (GK1.5)
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4+ T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Melanoma  
/
HY-P99054 Tusamitamab
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542).

Species: Human

Transmembrane Glycoprotein   ADC Antibodies  
Gastric Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-P9918 Tremelimumab
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P99971 Gemtuzumab
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein  
Cancer  
/
HY-P990673 Vandortuzumab
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein   Mitosis  
Castration-Resistant Prostate Cancer  
/
HY-P70684 CTLA-4 Protein, Human (HEK293, His)
The CTLA-4 protein is a key inhibitory receptor and a major negative regulator of T cell responses in coordination of immune regulation. Its unique property is its significantly increased affinity for B7 ligands (CD80/CD86) compared with CD28. CTLA-4 Protein, Human (HEK293, His) is the recombinant human-derived CTLA-4 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P70676 PD-1 Protein, Cynomolgus (HEK293, His)
PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P73341 PD-1 Protein, Canine (HEK293, Fc)
Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P70706 CTLA-4 Protein, Mouse (HEK293, Fc)
CTLA-4 is a key inhibitory receptor that serves as a major negative regulator of T cell responses in immune regulation. Its unique property is that its affinity to B7 ligands (CD80/CD86) is significantly higher than that of CD28. CTLA-4 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CTLA-4 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P71991 CTLA-4 Protein, Mouse (HEK293, His)
CTLA-4 Protein, Mouse (HEK293, His) is a recombinant CTLA-4 protein with a His-flag. CTLA-4 Protein is a single-pass type I membrane protein and belongs to the CD28 receptor family. CTLA-4 is a negative immune regulator constitutively expressed on Treg cells.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P78191 PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P73342 PD-1 Protein, Canine (HEK293, His, solution)
Programmed cell death protein 1 (Pdcd1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. Pdcd1plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but Pdcd1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, His, solution) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P75320 CTLA-4 Protein, Canine (HEK293, His)
CTLA-4 protein inhibits T-cell responses as a critical negative regulator, with a stronger affinity for CD80 and CD86 than CD28. This affinity allows CTLA-4 to effectively suppress T-cell activation and regulate immune responses, maintaining a delicate equilibrium in T-cell-mediated immunity. CTLA-4 Protein, Canine (HEK293, His) is the recombinant canine-derived CTLA-4 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P73345 PD-1 Protein, Human (HEK293, His-Fc)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, His-Fc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P705403 PD-1 Protein, Mouse (Biotinylated, HEK293, His-Avi)
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived PD-1 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P70547 PD-1 Protein, Cynomolgus (HEK293, Fc)
PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P78889 CTLA-4 Protein, Mouse (Biotinylated, HEK293, His-Avi)
CTLA-4 is a key inhibitory receptor that serves as a major negative regulator of T cell responses in immune regulation. Its unique property is that its affinity to B7 ligands (CD80/CD86) is significantly higher than that of CD28. CTLA-4 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived CTLA-4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P75317 CTLA-4 Protein, Mouse (Biotinylated, HEK293, His)
CTLA-4 is a key inhibitory receptor that serves as a major negative regulator of T cell responses in immune regulation. Its unique property is that its affinity to B7 ligands (CD80/CD86) is significantly higher than that of CD28. CTLA-4 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived CTLA-4 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P78891 CTLA-4 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi)
CTLA-4 Protein, a pivotal inhibitory receptor, is a primary negative modulator of T-cell responses in immune regulation. Its distinctive property lies in significantly higher affinity for B7 ligands (CD80/CD86) than the stimulatory coreceptor CD28. Outcompeting CD28 for ligand engagement, CTLA-4 exerts a suppressive influence on T-cell activation, mitigating excessive immune responses in the intricate landscape of immune regulation. CTLA-4 Protein, Cynomolgus/Rhesus macaque (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus, Rhesus Macaque-derived CTLA-4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CTLA-4 Protein, Cynomolgus/Rhesus macaque (Biotinylated, HEK293, His-Avi) is 124 a.a., with molecular weight of 20-26 kDa.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P7838 CTLA-4 Protein, Cynomolgus (HEK293, His)
CTLA-4 Protein, a pivotal inhibitory receptor, is a primary negative modulator of T-cell responses in immune regulation. Its distinctive property lies in significantly higher affinity for B7 ligands (CD80/CD86) than the stimulatory coreceptor CD28. Outcompeting CD28 for ligand engagement, CTLA-4 exerts a suppressive influence on T-cell activation, mitigating excessive immune responses in the intricate landscape of immune regulation. CTLA-4 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CTLA-4 protein, expressed by HEK293 , with N-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P700808 PD-1 Protein, Mouse (Biotinylated, HEK293, Fc)
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1 Protein, Mouse (Biotinylated, HEK293, Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P704300 CTLA-4 Protein, Cynomolgus (HEK293, hFc)
CTLA-4 Protein, a pivotal inhibitory receptor, is a primary negative modulator of T-cell responses in immune regulation. Its distinctive property lies in significantly higher affinity for B7 ligands (CD80/CD86) than the stimulatory coreceptor CD28. Outcompeting CD28 for ligand engagement, CTLA-4 exerts a suppressive influence on T-cell activation, mitigating excessive immune responses in the intricate landscape of immune regulation. CTLA-4 Protein, Cynomolgus (HEK293, hFc) is the recombinant cynomolgus-derived CTLA-4 protein, expressed by HEK293, with C-hFc labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P705071 PD-1 Protein, Mouse (Biotinylated, HEK293, Fc-Avi)
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1, Mouse (Biotinylated, HEK293, Fc-Avi) is the recombinant mouse-derived PD-1 protein, expressed by HEK293, with C-Avi;C-hFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P705180 CTLA-4 Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi)

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CTLA-4

/
HY-P705418 PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi-His)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1, Human (Biotinylated, HEK293, Fc-Avi-His) is the recombinant human-derived PD-1 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P86649 CD86 Antibody (YA6341)
CD86 Antibody (YA6341) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81839A PD-L2 Antibody (YA3391)
PD-L2 Antibody (YA3391) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L2.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81075 CTLA4 Antibody (YA3503)
CTLA4 Antibody (YA3503) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTLA4.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84582 PD-1 Antibody (YA4279)
PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P85094 CD80 Antibody (YA4786)
CD80 Antibody (YA4786) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD80.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P81603 PD-L2 Antibody (YA1348)
PD-L2 Antibody (YA1348) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81668 CD80 Antibody (YA1413)
CD80 Antibody (YA1413) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD80.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81839 PD-L2 Antibody (YA1584)
PD-L2 Antibody (YA1584) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83254 alpha/beta Synuclein Antibody (YA2999)
alpha/beta Synuclein Antibody (YA2999) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha/beta Synuclein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84966 CTLA4 Antibody (YA7081)
CTLA4 Antibody is a non-conjugated antibody, targeting to CD152/CTLA4.

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P85804 CD80 Antibody (YA5496)
CD80 Antibody (YA5496) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD80.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P85925 PD-1 Antibody (YA5617)
PD-1 Antibody (YA5617) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87178 CTLA4 Antibody(YA6870)
CTLA4 Antibody(YA6870) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTLA4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84581 PD-1 Antibody (YA4278)
PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84581A PD-1 Antibody (YA4278)(PBS only)
PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84582A PD-1 Antibody (YA4279)(PBS only)
PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86682 CD86 Antibody (YA6374)
CD86 Antibody (YA6374) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86682A CD86 Antibody (YA6374)(PBS only)
CD86 Antibody (YA6374) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD86.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K3014D Bi-27 Serum-free Supplement (50×), Antioxidant-Free

MCE Bi-27 Serum-free Supplement (50×), Antioxidant-Free is a customized neuronal culture supplement developed by removing antioxidants components (such as vitamins, superoxide dismutase, catalase, etc.) from the standard Bi-27 formulation. It is specifically designed for investigating the roles of reactive oxygen species (ROS) in aging, cytotoxicity, apoptosis, and chronic neurological diseases. This formulation provides a stable culture environment for mechanistic studies without the interference of exogenous antioxidants.

Cell Biology Cell Culture Cell Culture Supplements

/

Keywords

multiple sclerosis | immune checkpoint inhibitors | PD-1 | CTLA-4 | demyelination | neurologic immune-related adverse events